You are here

GENVEC, INC.

Company Information
Address
910 CLOPPER RD STE 220N
GAITHERSBURG, MD 20878-1353
United States


http://www.genvec.com

Information

UEI: N/A

# of Employees: 15


Ownership Information

HUBZone Owned: No

Socially and Economically Disadvantaged: No

Woman Owned: No



Award Charts




Award Listing

  1. Development of a Highly Tumor-Specific Adenovirus Vector

    Amount: $96,739.00

    DESCRIPTION (provided by applicant): Despite a number of newly approved drugs, cancer is responsible for over 20% of all deaths and will soon overtake heart disease as the main killer in the Western w ...

    SBIRPhase I2004Department of Health and Human Services National Institutes of Health
  2. Alternate Delivery of Potent Antiangiogenic Agent-AdPEDF

    Amount: $139,924.00

    DESCRIPTION (provided by applicant) Exudative age-related macular degeneration (AMD) and proliferative diabetic retinopathy (DR), due to aberrant choroidal and retinal neovascularization respectively, ...

    SBIRPhase I2004Department of Health and Human Services National Institutes of Health
  3. Targeting Adenovirus Vectors to Ovarian Cancer

    Amount: $356,058.00

    DESCRIPTION (provided by applicant): Despite significant improvements in the management of ovarian cancer, approximately 13,900 women per year in the United States are expected to ultimately fail stan ...

    SBIRPhase I2004Department of Health and Human Services National Institutes of Health
  4. Targeted, Alternate Serotype Vector for Ovarian Cancer

    Amount: $478,188.00

    DESCRIPTION (provided by applicant): Despite significant improvements in the management of ovarian cancer, approximately 13,900 women per year in the United States are expected to ultimately fail stan ...

    SBIRPhase I2004Department of Health and Human Services National Institutes of Health
  5. Evaluation of Adenovirus Vectors in the Eye

    Amount: $99,999.00

    DESCRIPTION (provided by applicant): This proposal is designed to test an improved gene delivery strategy for the treatment of age-related macular degeneration (AMD). Wet AMD and diabetic retinopathy ...

    SBIRPhase I2003Department of Health and Human Services National Institutes of Health
  6. Protein Production of PEDF-Potent Antiangiogenic Agent

    Amount: $99,876.00

    DESCRIPTION (provided by applicant): Exudative age-related macular degeneration (AMD) and proliferative diabetic retinopathy (DR), due to aberrant choroidal and retinal neovascularization respectively ...

    SBIRPhase I2003Department of Health and Human Services National Institutes of Health
US Flag An Official Website of the United States Government